Rochester is at the forefront of developing new E. coli vaccine
Antibiotic-Resistant Strains Posing Life-Threatening E. Coli Infections.
Rochester, N.Y. – E. coli are bacteria found in the environment, foods and intestines of people and animals. Each year, E. coli causes hundreds of thousands of infections in the United States alone. While many infections can be harmless, in recent years, some strains of E. coli have developed a resistance to antibiotics. This poses a significant health threat, especially for older individuals who are at a higher risk of infection. Rochester Clinical Research (RCR) is currently developing a vaccine to prevent blood, lung, and systemic urinary tract (Kidney) infections from E. coli. The vaccine would cover 10 of the most problematic subtypes of E. coli, which are also subtypes where drug resistance to antibiotics is developing.
Matthew Davis, MD, Principal Investigator for the E. coli vaccine research study is enthusiastic about the clinical trial. “E. coli is the leading and rising cause of bacteremia and bloodstream infections due to a worldwide emergence of multi-drug resistant strains making treatment harder. Being on the forefront of developing an E. coli vaccine allows us to potentially help those here in Rochester and eventually worldwide. Systemic E. coli infection is difficult to treat, so being able to prevent it is the best way of treating it.”
- coli infection is acquired by susceptible individuals, often living in community nursing homes and hospital settings. When someone contracts a strain of E. coli that makes them ill, it can cause sepsis, or a severe blood infection. Sepsis is the body’s deadly response to the infection and results in high rates of hospitalizations and even death. One-third of people who develop sepsis die.
RCR is currently enrolling individuals between the ages of 60 – 85 years old to participate in an E. coli vaccine research study. Participants must be generally healthy and have never received a Prevnar 13 pneumonia vaccine. Compensation is available up to $300 for those who qualify.
The clinical trial will hopefully lead to the development of a safe and effective E. coli vaccine which would be used primarily in the elderly or other patients who are at high risk for E. coli infections to eventually be used in older adults to help protect them against E. coli that may cause sepsis.
For more information about this research study opportunity, visit the RCR website at www.rcrclinical.com or call 585-288-0890.
About Rochester Clinical Research:
Rochester Clinical Research was founded in 1994 with the objective of providing the Greater Rochester area with access to a premier clinical research facility. The goal of the organization is to advance new medical treatments and improve the quality of life for individuals everywhere. Rochester Clinical Research puts great pride in the relationships it has with its sponsors, volunteers, and staff. The organization strives toward advancing new medicines and catching up with diseases before they become a problem.
# # #